Kornimate/medical-research-clean huggingface dataset:
onion, cardiovascular risk markers and gene expression

Conditions: Blood Pressure; Coagulation Delay

Summary: aims: the aims are to investigate whether: * increased intake of onion (powder) affects plasma lipid profile, blood pressure, indices of insulin sensitivity and blood coagulation. * increased intake of onion (powder) affects the expression/activity of enzymes in the defence against foreign substances, e.g. reactive oxygen species, and whether polymorphisms in some of the involved genes may modulate the effect. * polymorphisms involved in the metabolism/effect of bioactive components in onion modulate the excretion of metabolites or modulate some of the outcome variables in the study. other aims are to try to identify biomarkers for onion consumption in plasma, urine and feces and to investigate whether onion affects the secretion of fat and bile acids. hypotheses: the investigators hypothesize that: * 2 weeks of increased onion intake will improve the plasma lipid profile * 2 weeks of increased onion intake will increase the metabolism of potentially harmful substances (such as ros and free radicals) through a change in the expression or activity of certain enzymes. * that these effects are modulated by common gene variants (polymorphisms)

in a randomized controlled crossover design, participants will receive 2 daily meals with or without onion powder for 2 weeks. between the two 2-week period is a 4-week wash-out period. one week before and during each intervention period, the participants will be instructed to avoid consumption of onion, garlic and all foodstuffs containing the same bioactive components (polyphenols, sulfur-molecules)as in onion. this includes a number of vegetables and fruits, condiments, tea, chocolate, red wine etc. fasting blood samples will be drawn before and after (on 2 separate days) each intervention period, where also weight and blood pressure are measured. participants will collect 24-hour urine and feces samples twice before and at completion of each intervention period. after the fasting blood sampling on the first blood sampling day in each period, participants will receive a test meal (with 10 g onion powder or placebo, i.e. 8.5 g sucrose+ 2 g soy protein isolate). the acute effects will be studied by blood sampling and urine sampling 0, 2, 4 and 24 hours after the test meal.

Eligibility criteria:
inclusion criteria: * healthy * bmi 25-40 * no daily medication (except thyroid hormone, stomach acid lowering drugs, mild blood pressure lowering drugs and anti-depressants) * not strenuous exercise \>10 hours/week * no blood donation 3 months before or during the study exclusion criteria: * diabetes, cvd, hepatitis, hiv/aids * cancer or cancer treatment within last 6 months * smoking * simultaneous participation in other research projects

Keywords: onion cardiovascular disease metabolomics gene expression biomarker
study of the impact of cheese matrix on postprandial lipemia: a clinical study

Conditions: Healthy

Summary: dairy products consumption is widely recommended in a healthy diet not only for bone growth and maintenance, but also as a protein, calcium and magnesium sources for an adequate diet. however, dairy products are a major dietary source of saturated fat that is associated with increased risk of coronary heart disease. ln this context, dietary guidelines still advocate a restriction in dietary saturated fat for optimal heart health. nevertheless, the association between saturated fat and the risk of heart disease remains highly controversial within the scientific community. there is also emerging evidence that the impact of dietary saturated fat will be significantly influenced by the food matrix through which it is provided. recent studies indicate that cheese could have a major influence on intestinal fat absorption and the magnitude of the after meal release of fat in blood circulation. this is of interest because substantial evidence exists indicating that elevated levels of the after meal fat levels are associated with increased cardiovascular risk. therefore, the improvement of the after meal fat levels produced by cheese consumption could well be part of novel therapeutic approaches contributing to improve cardiovascular risk. the general objective of the proposed research is to investigate how cheese consumption affects the after meal release of fat in blood circulation in healthy subjects. our hypothesis is that, compared to butter, cheese consumption will have a beneficial impact on the after meal fat levels in healthy subjects. favourable results from the proposed study will provide novel and much warranted evidence on the importance of considering changes in the after meal fat levels, not only bad cholesterol, as part of the on-going saturated fat-heart disease debate and that cheese should indeed be part of a healthy diet.


Eligibility criteria:
inclusion criteria: * age between 18-65 years (men and women) exclusion criteria: * smokers (more than 1 cigarette/d) * body weight variation more than 10% during the last 6 months prior to the study baseline * bmi more than 35 kg/m2 * previous history of cardiovascular disease * subjects with type 2 diabetes * subjects with monogenic dyslipidemia * subjects taking anti-inflammatory drugs * subjects with endocrine or gastrointestinal disease * allergy/intolerance to dairy * clinical use of vitamin d and calcium supplements * vegetarians * subjects who are in situation or have a condition that, in the opinion of the investigators, may interfere with optimal participation in the study
german national registry for nss

Conditions: Kidney Neoplasm

Summary: the g-ness registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses. analyses of data aims at identifying key factors determining the quality of surgical care in this patient population.

today the majority of patients with renal tumors is diagnosed with localized disease amenable to nephron-sparing surgery (nss). partial nephrectomy (pn) constitutes the reference standard treatment for small renal masses according to international guidelines. open pn ist still the predominant apporach in germany, but the use of minimally-invasive surgery has continously increased over the last decades. specifically, robotic surgery is on the rise and may facilitate the adoption of a minimally-invasive pn approach even in more complex renal tumours. real world data on the outcomes of pn according to the surgical approach are limited. data from cancer registries and health insurance databases usually lack important information an key patient und tumour characteristics, such as tumour complexity. the g-ness registry database aims at prospectively collecting such clinical and outcome data from patients undergoing pn. data collection includes perioperative variables on patient characteristics, tumour location and complexity, surgical approach, intra-/postoperative complications, and kidney function. follow-up based on questionnaires is conducted after predefined intervals (i.e. 30 days, 12 months, 24 months, and 60 months) in order to receive information on long-term kidney function, comorbidities, and survival. the information received from the database can help to better define the optimal surgical care for patients with renal masses.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * written informed consent * localized renal parenchymal mass amenable to nephron-sparing surgery * adequate imaging of the abdomen (ct or mr with contrast) exclusion criteria: * patient with (or suspected to have) urothelial cancer of the kidney * prior nephron-sparing surgery on ipsilateral kidney * metastasized renal cell carcinoma
effect of different treatments on the prognosis of early cervical cancer: a multicenter, prospective, real-world study

Conditions: Cervical Cancer

Summary: to observe the effects of different treatments on the oncological outcome and complications of early cervical cancer (2018 figo stage ia1 with lymphovascular space invasion and ia2-iia2 cervical cancer). this study prospectively collecting enrolled cervical cancer patients clinical data and outcome from june 2020 to june 2025. (classification factors: preoperative neoadjuvant treatment , surgical approach, type of hysterectomy, whether to receive radiochemotherapy) . this study is an observational study, and segmented analysis according to different treatment methods.

objectives: to observe the effects of different treatments on the oncological outcome and complications of early cervical cancer (2018 figo stage ia1 with lymphovascular space invasion and ia2-iia2 cervical cancer). study design: we obtained the demographic, clinical, treatment hospital and complication data of patients with cervical cancer undergoing radical hysterectomy from 2004 to 2015 at 37 hospitals. the patients were assigned into groups. classification factors: preoperative neoadjuvant treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy) , surgical approach (abdomincal, laparoscopic, vaginal, robotic surgery), type of hysterectomy (type b, type c1, type c2), primary treatment (radiochemotherapy or surgery). laparoscopic and abdominal surgery groups. the differences in the survival, complication rates, quality of life, and cost were analyzed using univariate and multivariable logistic regression models.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed primary adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or other histological types carcinoma of the uterine cervix. 2. patients with histologically confirmed stage ia1 (with lymph vascular invasion), figo 2018 stage ia2 to iia2. 3. underwent radical hysterectomy or radiochemotherapy. 4. ecog performance status of 0 or 1. exclusion criteria: 1. life expectancy is less than 6 months 2. no prior malignancy 3. ecog performance status of 2 to 5.

Keywords: cervical cancer preoperative treatment surgical approach hysterectomy type radiochemotherapy
laparoscopic assisted transvaginal cholecystecomy

Conditions: Cholelithiasis

Summary: laparoscopic cholecystectomy is currently the standard procedure for removing the gallbladder. this procedure usually requires the insertion of four trocars into the abdomen for passage of laparoscopic instruments; each trocar requires a small incision, which results in postoperative pain and scarring. there has recently been a tremendous surge in interest within the surgical community to further reduce the pain, invasiveness, and cosmesis of laparoscopic surgery. to achieve this goal, surgeons are either reducing the number of trocars placed through the abdominal wall or eliminating them completely the goal of this project is to evaluate the feasibility of performing transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization. this has the potential to decrease postoperative pain, improve cosmesis, and lead to a shorter recovery following cholecystectomy.

20 female patients will be enrolled. patients who are scheduled to undergo elective laparoscopic cholecystectomy will be invited to participate in this study. the laparoscopic instrumentation will be sterilized using standard methods. conventional and new laparoscopic and endoscopic equipment will be used for this project; all equipment is commercially available and is fda-approved for laparoscopic procedures. access will be obtained into the peritoneal cavity at the umbilicus in a standard fashion, either by use of a veress needle technique or by insertion of a trocar using the open technique. through a single umbilical incision, a 5mm trocar will be placed into the peritoneal cavity. a 5mm laparoscope will then be inserted into the peritoneal cavity. this will be used to monitor safe peritoneal entry of a dilating12mm transvaginal trocar. subsequent operative visualization will be by use of a flexible endoscope which will be placed through the transvaginal port. the gallbladder will be retracted using sutures as well as endoscopic and / or laparoscopic graspers. in order to obtain the critical view of safety \[5\] the cystic duct and artery will be dissected, ligated and divided by use of conventional laparoscopic and new articulating instruments. the dissected gallbladder will be retrieved transvaginally. if for any reason suitable retraction or dissection cannot be performed using the transvaginal strategy, the case will be promptly converted to a standard laparoscopic approach by the insertion of additional transabdominal trocars.

Eligibility criteria:
inclusion criteria: * scheduled to undergo elective laparoscopic cholecystectomy * women 18-75 years of age * english or spanish speaking exclusion criteria: * american society of anesthesiologists (asa) classification of ≥ 3 * morbid obesity (bmi ≥35) * pregnant women * acute cholecystitis * any ongoing intra-abdominal infection * prior upper abdominal or pelvic surgery and/or adhesions * virgins * women with an active sexually transmitted disease or any vaginal infection * history of dyspareunia

Keywords: cholecystectomy gall stone surgery scarless surgery cholelithiasis
circulating anti-beta2-glycoprotein antibodies and endothelial dysfunction

Conditions: Peripheral Arterial Disease

Summary: circulating anti-beta2-glycoprotein antibodies have been associated with coronary artery disease and peripheral arterial disease. this auto-antibodies could activate endothelial cells leading to the expression of leukocyte adhesion molecules and increasing the release of pro-inflammatory cytokines. on the other hand, endothelial dysfunction of atherosclerotic patients acts as a primary pathogenic event, as it occur before structural changes are evident on angiogram or ultrasound scan. loss of endothelial normal function causes vasoconstriction, local coagulation alterations and an increase arterial wall proliferation. this situation s been attributed to a reduction in nitric oxide bioactivity, and to an increase oxygen-free radical formation in the context of the pro-inflammatory status found in atherosclerosis. hypothesis: circulating anti-beta2-glycoprotein i antibodies could be associated with endothelial dysfunction and nitric oxide metabolism disruption en patients with peripheral arterial disease.


Eligibility criteria:
inclusion criteria: * male gender * peripheral arterial disease diagnosis * intermittent claudication. * hemodynamic confirmation of the disease through non-invasive vascular studies. exclusion criteria: * autoimmune disease * previous revascularization of the ischemic limb. * ischemic ulcers * previous history of organ transplants. * treatment with immunosuppressors

Keywords: anti-beta2-glycoprotein antibodies peripheral arterial disease inflammation nitric oxide endothelial dysfunction
clinical study to evaluate dental plaque

Conditions: Gingival Diseases

Summary: clinical research study to determine anti-plaque efficacy of a prototype toothpastes for a 3 week brushing regiment.


Eligibility criteria:
inclusion criteria: * male or female volunteers at least 20 - 51 years of age * good general health * must sign informed consent form * minimum of 15 natural uncrowned teeth (excluding third molars) must be present * no history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study exclusion criteria: * subjects unable or unwilling to sign the informed consent form * medical condition which requires pre-medication prior to dental visits/procedures * moderate or advanced periodontal disease or heavy dental tartar (calculus) * 5 or more decayed untreated dental sites at screening (cavities) * other disease of the hard or soft oral tissues. * impaired salivary function (e.g. sjogren's syndrome or head and neck irradiation). * use of medications that are currently affecting salivary function * use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1 * pregnant or nursing women * participation in any other clinical study within 1 week prior to enrollment into this study * use of tobacco products * subjects who must receive dental treatment during the study dates * current use of antibiotics for any purpose * presence of an orthodontic appliance which interferes with plaque scoring * history of allergy to common toothpaste ingredients * history of allergy to arginine (amino acid) * immune compromised individuals (hiv, aids, immuno suppressive drug therapy)
a study of fycompa (perampanel) in korean participants

Conditions: Epilepsy

Summary: the purpose of this post-marketing surveillance is to observe the following items regarding the safety profile of fycompa (perampanel) film-coated tablets and oral suspension in normal clinical practice setting: serious adverse event/adverse drug reaction profile, unexpected adverse event/adverse drug reaction profile, already known adverse drug reaction profile, non-serious adverse event profile and other information related to the product's safety and effectiveness.


Eligibility criteria:
inclusion criteria: 1. participants with approved indication for fycompa (perampanel) in korea as follows: * monotherapy (film-coated tablets) o 4 years and older partial-onset seizures: therapy for treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy * adjunctive therapy (film-coated tablets \& oral suspension) * 4 years and older partial-onset seizures: therapy for treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy * 7 years and older primary generalized tonic-clonic seizures: therapy for treatment of primary generalized tonic-clonic seizures in participants with idiopathic generalized epilepsy 2. participants who have written consent for use of personal and medical information for the study purpose exclusion criteria: 1. hypersensitivity to the active substance or to any of the excipients of this medicine 2. in case of fycompa film-coated tablets, fycompa tablets contains lactose; therefore, participants with rare hereditary problems of galactose intolerance, the lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine. in case of fycompa oral suspension, fycompa suspension contains sorbitol; therefore, participants with rare hereditary problems of fructose intolerance should not take this medicine. 3. other participants judged to be inadequate to participate in the study by doctor

Keywords: epilepsy partial-onset seizures secondarily generalized seizures perampanel post marketing surveillance primary generalized tonic-clonic seizures idiopathic generalized epilepsy
effectiveness of percutaneous neuromodulation vs pharmacological treatment in cancer patients with anterior knee pain

Conditions: Pain Cancer

Summary: the goal of this clinical trial is to compare in cancer patients: is ultrasound-guided percutaneous neuromodulation useful for anterior knee pain relief in cancer patients? participants will receive treatments of ultrasound-guided percutaneous neuromodulation and pharmacological treatment researchers will compare ultrasound-guided percutaneous neuromodulation versus pharmacological treatment to see if anterior knee pain is reduced

unhealthy lifestyles, an aging population and increased life expectancy increase the likelihood of cancer. knee pain is one of the most common symptoms that cause functional incapacity, which requires the search and improvement of its assessment, prevention and treatment tools. physiotherapists are currently using ultrasound-guided percutaneous neuromodulation clinically. it is an easy process to perform, non-invasive, safe and economical. traditional therapies have been and will continue to be useful. the decrease in manufacturing costs of assessment tools such as ultrasound and neuromodulator treatment in recent years has made the acquisition of these equipment as intervention tools economical. this is because they have been shown to be useful for improving function and reducing pain. opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects. in order to improve these symptoms, it is essential to have an objective knowledge of the changes produced by neuromodulation and to be able to measure the variation of pain experienced by patients. it has been demonstrated in recent years that assessment tools such as ultrasound and myotonometer are very useful, safe and non-invasive procedures, both have been consolidated as assessment tools that can evaluate changes and analyze the contractile properties of soft tissue quickly and safely. there are abundant literature on this subject. therefore, researchers suggest conducting research that improves and provides new data on the efficacy and effectiveness of treatment of ultrasound-guided percutaneous neuromodulation.

Eligibility criteria:
inclusion criteria: the proposed inclusion criteria for the study are as follows: * age between 18 and 65. * pain in the front of the knee. * taking drug therapy for lower-extremity pain. * diagnosis of painful pathology in the anterior aspect of the knee secondary oncologic. exclusion criteria: the exclusion criteria are: * traumatic history * have had any type of analgesic treatment in the last 4 weeks (clinical, physical or orthostatic) * no need for drug treatment within the last 30 days of study initiation.

Keywords: cancer pain anterior knee pain nmp
association of different doses of clonidine in caudal epidural anesthesia for hypospadias surgery

Conditions: Postoperative Pain

Summary: the use of increasing doses of clonidine ssociated to bupivacaine in caudal epidural block provides better postoperative analgesia compared whit analgesia provide by bupivacaine alone it is a randomized, double blind study, involving 80 children with ages from 1 to 10 years old, following eletive hypospadias surgery, under general anesthesia and caudal epidural block . the patients will be divided into 4 groups: bupivacaine alone, bupivacaine plus clonidine 1mcg/kg, bupivacaine plus clonidine 2 mcg/kg, bupivacaine plus clonidine 3 mg/kg. the peroperative consumption of anesthetics gases, heart rate and arterial blood pressure will be recorded. postoperative pain will be evaluated by using flacc scale ( faces , legs, activity , cry , consolability ) . requiriments for supplementary postoperative analgesia at 24 h will be avaiable.

it is a randomized, double blind study, involving 80 children with ages from 1 to 10 years old, following eletive hypospadias surgery, under general anesthesia and caudal epidural block . the patients will be divided into 4 groups: bupivacaine alone, bupivacaine plus clonidine 1mcg/kg, bupivacaine plus clonidine 2 mcg/kg, bupivacaine plus clonidine 3 mg/kg. the peroperative consumption of anesthetics gases, heart rate and arterial blood pressure will be recorded. postoperative pain will be evaluated by using flacc scale ( faces , legs, activity, cry , consolability ) . requiriments for supplementary postoperative analgesia at 24 h will be avaiable. postoperative hemodynamics parameters will be recordes at 24 h.

Eligibility criteria:
inclusion criteria: * children 1 - 10 years old. * asa i e ii ( american society of anesthesiology) * hypospadias surgery exclusion criteria: * parents refuse * infection * coagulation disorders * allergy to anesthetics * abnormalities of the sacral spine

Keywords: analgesia bupivacaine clonidine